Holen Sie sich die Stockscreener-App
10.86
7.57%
-0.89
Handel nachbörslich:
10.72
-0.14
-1.29%
Schlusskurs vom Vortag:
$11.75
Offen:
$11.73
24-Stunden-Volumen:
1.71M
Relative Volume:
0.94
Marktkapitalisierung:
$1.02B
Einnahmen:
Nettoeinkommen (Verlust:
$-313.94M
KGV:
-3.0975
EPS:
-3.506
Netto-Cashflow:
$-284.57M
1W Leistung:
-19.08%
1M Leistung:
-16.20%
6M Leistung:
+395.89%
1J Leistung:
+132.55%
1-Tages-Spanne:
$10.80
$11.73
1-Wochen-Bereich:
$10.80
$13.56
52-Wochen-Spanne:
$1.50
$16.33
Replimune Group Inc Stock (REPL) Company Profile
Firmenname
Replimune Group Inc
Sektor
Branche
Telefon
(781) 222-9600
Adresse
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
10.86 | 1.02B | 0 | -313.94M | -284.57M | -3.506 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2026-08-04 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2026-07-31 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2026-07-31 | Hochstufung | Wedbush | Neutral → Outperform |
| 2026-06-30 | Hochstufung | BMO Capital Markets | Underperform → Outperform |
| 2026-06-26 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2026-05-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2026-04-13 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2026-04-13 | Herabstufung | H.C. Wainwright | Buy → Sell |
| 2026-04-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2026-04-13 | Herabstufung | Jefferies | Buy → Hold |
| 2026-04-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-04-13 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-04-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-11-03 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-10-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-09-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Herabstufung | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-06-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-17 | Eingeleitet | BTIG Research | Buy |
| 2020-11-02 | Eingeleitet | Jefferies | Buy |
| 2020-10-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-09-04 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-25 | Eingeleitet | Wedbush | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Eingeleitet | JP Morgan | Overweight |
| 2018-08-14 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
Why Is REPL Stock Soaring 127% After Hours Today? - Stocktwits
Replimune Group, Inc. (REPL) Options Chain - Yahoo! Finance Canada
Replimune Group, Inc. (REPL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus - Yahoo Finance
(REPL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
7R8.HM Interactive Stock Chart | Replimune Group Inc. R Stock - Yahoo! Finance Canada
Levi & Korsinsky Urges Replimune Group, Inc. (REPL) Shareholders to Act Before Lead Plaintiff Deadline October 5, 2026 - ACCESS Newswire
FDA Staff Raise Concerns On Replimune’s Skin Cancer Drug – REPL Stock Crashes 32% Today Ahead Of Advisory Meeting This Week - Stocktwits
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - WBOC TV
Replimune Group, Inc. (REPL) Options Chain - Yahoo! Finance Canada
Levi & Korsinsky Urges Replimune Group, Inc. (REPL) Shareholders to Act Before Lead Plaintiff Deadline October 5, 2026 - ACCESS Newswire
Securities Lawsuit Alert: Replimune Group, Inc. (REPL)Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire
Lost Money on Replimune Group, Inc. (REPL)? Join Class Action Before October 5, 2026Contact Levi & Korsinsky - ACCESS Newswire
REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & - GlobeNewswire
REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & - GlobeNewswire
REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th - GlobeNewswire Inc.
Insiders At Replimune Group Sold US$1.6m In Stock, Alluding To Potential Weakness - Moomoo
REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class ActionContact the Firm - FinancialContent
Replimune Group, Inc. (7R8.MU) stock price, news, quote and history - Yahoo Finance Australia
Replimune launches melanoma therapy in US market - Investing.com
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma - FinancialContent
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma - Yahoo Finance
Replimune CEO and CFO sued for allegedly mislea... - Pluang
SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026REPL - PR Newswire
SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026REPL - TradingView
REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities LawsuitContact Levi & Korsinsky - Morningstar
REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities LawsuitContact Levi & Korsinsky - PR Newswire
Operating margin % of Replimune Group, Inc. – HAN:7R8 - TradingView
Lost Money on Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky Before October 5, 2026 to Join Class Action - ACCESS Newswire
REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investors - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, - GlobeNewswire
REPL Investor Alert: Replimune Group, Inc. Securities Class Action NoticeContact Levi & Korsinsky - GlobeNewswire
ETFs Investing in Replimune Group, Inc. Stocks - TradingView
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, - GlobeNewswire
Replimune faces securities lawsuit over alleged misleading FDA trial data claims on RP1 drug resubmission. - Pluang
REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026 - PR Newswire
REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
Securities Lawsuit Alert: Replimune Group, Inc. (REPL)Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire
Replimune stock gains as share authorization doubles - AD HOC NEWS
Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investors - GlobeNewswire
REPL Stock Clocks Worst Day In Over 3 Months — New FDA Documents Leave Wall Street Awaiting Another Rejection For Cancer Drug - Stocktwits
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Replimune Group, Inc. (REPL) Stock Analysis: A Potential 51.52% Upside In Biotech Innovations - DirectorsTalk Interviews
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action LawsuitInvestors With Losses May Contact SueWallSt - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. LawsuitREPL - Morningstar
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REPL Stock DropRobbins LLP Reminds Investors They May Be - GlobeNewswire
Finanzdaten der Replimune Group Inc-Aktie (REPL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Replimune Group Inc-Aktie (REPL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hill Emily Luisa | Chief Financial Officer |
Aug 10 '26 |
Sale |
12.97 |
11,448 |
148,481 |
225,108 |
| Xynos Konstantinos | Chief Medical Officer |
Aug 10 '26 |
Sale |
12.97 |
11,447 |
148,468 |
224,215 |
| Schwendenman Andrew | Chief Accounting Officer |
Aug 10 '26 |
Sale |
12.97 |
7,632 |
98,987 |
99,425 |
| Patel Sushil | Chief Executive Officer |
Aug 10 '26 |
Sale |
12.97 |
39,341 |
510,253 |
708,151 |
| Sarchi Christopher | Chief Commercial Officer |
Jun 01 '26 |
Sale |
9.24 |
12,000 |
110,880 |
180,962 |
| Schwendenman Andrew | Chief Accounting Officer |
May 18 '26 |
Sale |
5.08 |
7,894 |
40,102 |
107,057 |
| Sarchi Christopher | Chief Commercial Officer |
May 18 '26 |
Sale |
5.08 |
8,626 |
43,820 |
192,962 |
| Astley-Sparke Philip | Director |
May 18 '26 |
Sale |
5.08 |
17,657 |
89,698 |
1,412,414 |
| Patel Sushil | Chief Executive Officer |
May 18 '26 |
Sale |
5.08 |
37,324 |
189,606 |
747,492 |
| Hill Emily Luisa | Chief Financial Officer |
May 18 '26 |
Sale |
5.08 |
7,812 |
39,685 |
236,556 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):